

APPENDIX – SEARCH STRATEGIES (via OVID)

Home treatment vs. hospital treatment (Recommendations 1-2)

MEDLINE and EMBASE - RCTs

1. (home adj2 therapy).mp.
2. (inpatient adj5 therap*).mp.
3. *home care/
4. home.mp.
5. exp Thromboembolism/ or exp Venous Thromboembolism/
6. exp Pulmonary Embolism/
7. exp Venous Thrombosis/
8. Thrombophlebitis/
9. (DVT or VTE or PE).mp.
10. ((Pulmon\$ or vein or venous or lung) adj (Emboli\$ or thromb\$)).mp.
11. (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).mp.
12. (((deep or thromb* or stasis) adj2 (vein* or venous)) or (blood flow stasis or blood clot)).mp.
13. or/5-12
14. or/1-4
15. 13 and 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. Clinical Trials as topic.sh.
19. trial.ti,ab.
20. factorial*.ti,ab.
21. (crossover* or cross over*).ti,ab.
22. ((doubl* or singl*) adj blind*).ti,ab.
23. (assign* or allocat* or volunteer* or placebo*).ti,ab.
24. placebo.ab.
25. random*.ti,ab.
26. or/16-25
27. animals/ not humans/
28. exp Animals, Laboratory/
29. exp Animal Experimentation/
30. exp Models, Animal/
31. exp Rodentia/
32. (rat or rats or mouse or mice).ti.
33. or/27-32
34. 26 not 33
35. 15 and 34

MEDLINE and EMBASE – Observational studies

1. (home adj2 therapy).mp.
2. (inpatient adj5 therap*).mp.
3. *home care/
4. home.mp.
5. exp Thromboembolism/ or exp Venous Thromboembolism/
6. exp Pulmonary Embolism/
7. exp Venous Thrombosis/
8. Thrombophlebitis/
9. (DVT or VTE or PE).mp.
10. ((Pulmon\$ or vein or venous or lung) adj (Emboli\$ or thromb\$)).mp.
11. (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).mp.
12. (((deep or thromb* or stasis) adj2 (vein* or venous)) or (blood flow stasis or blood clot)).mp.
13. or/5-12
14. or/1-4

15. 13 and 14
16. epidemiologic studies/
17. exp case control studies/
18. exp cohort studies/
19. cross-sectional studies/
20. case control.ti,ab.
21. (cohort adj (study or studies or analys*)).ti,ab.
22. ((follow up or observational or uncontrolled or non randomi#ed or nonrandomi#ed or epidemiologic*) adj (study or studies)).ti,ab.
23. ((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort*)).ti,ab.
24. or/1-8
25. 15 and 24
26. limit 25 to yr="2011- 2019"

Choice of anticoagulant therapy (Recommendation 3)

MEDLINE and EMBASE - RCTs

1. dabigatran.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
2. pradaxa.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
3. rivaroxaban.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
4. xarelto.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
5. apixaban.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
6. Eliquis.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
7. Edoxaban.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
8. Lixiana.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
9. Savaysa.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui]
10. (betrixaban or PRT054021).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
11. (DU-176b or DU176b).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
12. (YM150 or YM-150 or LY517717 or LY-517717 or DU-176b or DU176*).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
13. (GW813893 or "Tak 442" or TAK442 or PD0348292 or GSK-813893 or GSK813893).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
14. Factor Xa Inhibitors.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. Thrombosis.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
17. Thromboembolism.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
18. Venous Thromboembolism.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
19. Pulmonary Embolism.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
20. (PE or DVT or VTE).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
21. 16 or 17 or 18 or 19 or 20
22. randomized controlled trial.pt.
23. random allocation/
24. double-blind method/
25. single-blind method/
26. randomi?ed controlled trial\$.mp.
27. Randomi?ed clinical trial\$.mp.
28. controlled clinical trial.pt.
29. ((singl\$ or double\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).mp.
30. random\$.mp.
31. placebo\$.mp.
32. cross-over studies.sh.
33. latin square.tw.
34. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
35. animals/ not humans/
36. 34 not 35
37. 15 and 21 and 36
38. limit 37 to yr="2015 -Current"
39. remove duplicates from 38

Use of fibrinolytic therapy (Recommendations 4-5)

MEDLINE and EMBASE – RCTs

1. (thrombus* or thrombopro* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
2. (PE or DVT or VTE).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
3. (vein* or ven*).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
4. 1 or 2 or 3
5. (thromboly* or fibrinoly*).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
6. (anistreplase or streptodornase or pro-urokinase or prourokinase or pro-uk or lumbrokinase or duteplase or lanoteplase or pamiteplase or reteplase or saruplase or staphylokinase or streptase or tenecteplase or desmoteplase or retevase).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
7. (tPA or t-PA or rtPA or rt-PA or plasminogen or plasmin or alteplase or actilyse).mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, dq, nm, kf, ox, px, rx, an, ui, sy]
8. 5 or 6 or 7
9. (random* or clinical trial).mp. or clinical trial.pt.
10. 4 and 8 and 9
11. limit 10 to yr="2016 -Current"

Use of compression stockings (Recommendation 6)

MEDLINE and EMBASE – RCTs

1. thromboembolism.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
2. venous thromboembolism.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
3. thrombosis.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
4. venous thrombosis.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, ui]
5. postthrombo* syndrom*.mp
6. post-thrombo* syndrom*.mp.
7. posttrombo* syndrom*.mp.
8. post-trombo* syndrom*.mp.
9. exp postthrombotic syndrome/
10. compression stocking*.mp.
11. elastic stocking*.mp.
12. exp stockings, compression/
13. randomized controlled trial.pt.
14. random allocation/
15. double-blind method/
16. single-blind method/
17. randomi?ed controlled trial\$.mp.
18. Randomi?ed clinical trial\$.mp.
19. controlled clinical trial.pt.
20. ((singl\$ or double\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).mp.
21. random\$.mp.
22. placebo\$.mp.
23. cross-over studies.sh.
24. latin square.tw.
25. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. animals/ not humans/
27. 25 not 26
28. 1 or 2 or 3 or 4
29. 5 or 6 or 7 or 8 or 9
30. 10 or 11 or 12
31. 27 and 28 and 29 and 30
32. limit 31 to yr="2009 -Current"
33. remove duplicates from 32

Duration, choice of treatment and additional management issues (recommendations 7-18)

MEDLINE and EMBASE – RCTs

- 1 exp Coumarins/
- 2 (coumarin\$ or chromonar or coumestrol or esculin or isocoumarin\$ or psoralen? or pyranocoumarin* or umbelliferone*).mp.
- 3 warfarin.mp. or Warfarin/ or warfant.mp.
- 4 (coumadine or warfant or coumadin or marevan or aldocumar or tedicumar).mp.
- 5 Acenocoumarol/ or acenocoumarol*.mp.
- 6 (Pradaxa or Dabigatran).mp.
- 7 (Rivaroxaban or Xarelto).mp.
- 8 ((vitamin k adj3 antagonis*) or antivitamin K).mp.
- 9 vitamin k/ai
- 10 (vk adj2 antagonis*).mp.
- 11 (endosaban or apixaban).mp.
- 12 BAY 59-7939.mp.
- 13 (BMS-562247 or edoxaban or DU-176b or betrixaban).mp.
- 14 YM150.mp.
- 15 TAK-442.mp.
- 16 LY517717.mp.
- 17 PD0348292.mp.
- 18 (VKA or VKAs).mp.
- 19 (NOACs or noac).mp.
- 20 (DOACs or doac).mp.
- 21 ((new or novel or direct) adj4 (oral anticoag* or oral anti coag*)).mp.
- 22 ((novel or new) adj2 (anticoag: or anti coag:)).mp.
- 23 or/1-22
- 24 thrombosis.mp. or exp Thrombosis/
- 25 exp Venous Thromboembolism/ or exp Thromboembolism/ or Thromboembolism*.mp.
- 26 (pulmonary adj3 embolism*).mp. or exp Pulmonary Embolism/ or (lung adj3 embolism*).mp.
- 27 (PE or DVT or VTE).mp.
- 28 ((vein* or ven*) adj2 thromb*).mp.
- 29 (thrombu* or thrombotic* or thrombolic* or thromboemb* or thrombo* or embol*).mp.
- 30 or/24-29
- 31 randomized controlled trial.pt.
- 32 random allocation/
- 33 double-blind method/
- 34 single-blind method/
- 35 randomi?ed controlled trial\$.mp.
- 36 Randomi?ed clinical trial\$.mp.
- 37 controlled clinical trial.pt.
- 38 ((singl\$ or double\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).mp.
- 39 random\$.mp.
- 40 placebo\$.mp.
- 41 cross-over studies.sh.
- 42 latin square:.tw.
- 43 or/31-42
- 44 animals/ not humans/
- 45 43 not 44
- 46 23 and 30 and 45
- 47 (2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014*).em,ed,dc.
- 48 46 and 47